MFSD11

Across TCGA pan-cancer cohorts, MFSD11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MFSD11 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MFSD11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MFSD11 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LSCC, PDAC, and HNSC are the cancer types where MFSD11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.676	0.890	<.001	40	view →
PDAC	DFS	Tertile	II,III,IV	0.474	0.830	.007	21	view →
HNSC	OS	Median	IV	0.898	0.628	.006	15	view →
CCRCC	DFS	Tertile	III,IV	0.561	0.863	.034	9	view →
GBM	OS	Median	All	0.736	1.000	<.001	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MFSD11–LSCC (DFS)

Open the LSCC breakdown →